Dovitinib (TKI258, CHIR258)
产品编号: DC4157
Featured
我们的合作伙伴:
中国地区超过5000个高品质化合物库存
应用领域
Dovitinib (TKI258; CHIR-258) 是多靶点的酪氨酸激酶抑制剂，抑制FLT3，c-Kit，FGFR1/3，VEGFR1/2/3 和 PDGFRα/β 的 IC50 值分别为1，2，8/9，10/13/8，27/210 nM。
| Cas No.: |
405169-16-6 |
| 名称: |
1-amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one |
| 别名: |
CHIR-258,CHIR 258 |
| SMILES: |
N(N)1C2=C(C(F)=CC=C2)C=C(C2=NC3=CC=C(N4CCN(C)CC4)C=C3N2)C1=O |
| 分子式: |
C21H21FN6O |
| 分子量: |
392.43 |
| 纯度: |
|
| 保存条件: |
2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
| Description: |
|
| In Vivo: |
|
| In Vitro: |
|
| References: |
CHIR-265 is an orally bioavailable small molecule with potential antineoplastic activity.CHIR-265 binds and inhibits Raf kinases, which may result in a reduction of tumor cell growth and proliferation, and tumor cell death. In addition, this agent inhibit |
| Kinase Assay: |
|
| Cell Assay: |
|
| Animal Administration: |
|
| References: |
|
MSDS
COA
| LOT NO. |
DOWNLOAD |
|
|
| 2018-0101 |
|
询盘
